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Abstract
Aim of the Study:
The aim of this study is to investigate the anti-metastatic effect of genipin and its underlying mechanism.
Experimental Approach:
healing and invasion chamber assays were introduced to examine the anti-migration and anti-invasion action of genipin in
human hepatocellular carcinoma cell HepG2 and MHCC97L; orthotopical implantation model was used for in vivo
evaluation. Gelatin Zymography, Immunoblotting, quantitative real-time polymerase chain reaction and ELISA assays were
used to study the mechanisms underlying genipin’s anti-metastatic effect.
Key Results: Genipin suppresses the motility and invasiveness of HepG2 and MHCC97L at non-toxic doses, which may be
correlated to the inhibition of genipin on MMP-2 activities in the cells. No significant reduced expression of MMP-2 was
observed either at mRNA or at protein level. Furthermore, genipin could specifically up-regulate the expression of TIMP-1,
the endogenous inhibitor of MMP-2 activities. Silencing of TIMP-1 by RNA interference abolishes genipin’s anti-metastaic
effect. Activation of p38 MAPK signaling was observed in genipin-treated cells, which is responsible for the TIMP-1
overexpression and MMP-2 inhibition. Presence of SB202190, the p38 MAPK inhibitor, attenuates the anti-metastatic
potential of genipin in hepatocellular carcinoma. Orthotopical implantation model showed that genipin could suppress the
intrahepatic metastatic as well as tumor expansion in liver without exhibiting potent toxicity.
Conclusion: Our findings demonstrated the potential of genipin in suppressing hepatocellular carcinoma metastasis, and
p38/TIMP-1/MMP-2 pathway may be involved as the key mechanism of its anti-metastasis effect.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most malignant
human cancers all over the world. As the primary cancer of the
liver, HCC accounts for over 85% of the liver cancer cases [1].
Hepatocellular carcinoma was newly diagnosed in more than half
of million people in the world annually [2], and has become one of
the most leading causes of death worldwide. It is the fifth common
malignant tumor in men while seventh common in women [1],
and it is the third common causes of cancer mortality all over the
world with the incidence rates are increasing every year [3].
Although currently different therapeutic strategies have developed,
the prognosis of HCC remains poor due to the high reoccurrence
rate and metastatic effect of HCC cells [4]. Incidence of
intrahepatic metastatic is high in hepatocellular carcinoma with
infiltrate growth pattern according to clinicopathologic study [5].
However, there’s no effective chemotherapeutic agent which could
prevent metastasis in hepatocellular carcinoma patients.
Genipin, the metabolite of geniposide, is a natural product
present in fruit of Gardenia jasminoides. Previous study shows that
geniposide is absorbed and transformed to genipin in the bowel,
indicating that genipin may be the major form of geniposide in
blood [6]. Genipin has been report to have anti-inflammatory [7],
anti-oxidative [8], anti-thrombotic [9] and neuroprotective
activities [10]. Some recent studies also present the anti-tumor
effect of genipin in some human cancer cells including cervical
cancer cells Hela, hepatoma cells Hep3B and prostate cancer cells
PC3 by inducing cell apoptosis [11–13]. However, there’s no
study reporting the anti-metastasis effect of genipin and its
underlying mechanism in human hepatocellular carcinoma.
In the present study, we investigated the anti-invasive effect of
genipin on human hepatocellular carcinoma. We found that
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Hepatocellular carcinoma is one of the most malignant human cancers with high metastatic potential.
The anti-metastatic potential of genipin was evaluated by both cell and animal model. Wound
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genipin exhibits no significant cytotoxicity to human hepatocellu-
lar carcinoma cells HepG2 and MHCC97L, however, genipin
could remarkably suppress the migration and invasion of the HCC
cells. Genipin presents inhibitory effect on the MMP-2 activities,
which is responsible for the invasiveness of cancer cells. Genipin
has no direct inhibitory effect on the enzyme activities of MMP-2
in vitro, instead, up-regulation of the MMP-2 inhibitor TIMP-1 by
genipin in HCC cells may contribute to its inhibition on MMP-2
enzyme activities. In addition, activation of p38 MAPK signaling
by genipin may be responsible for its anti-invasive effect in HCC.
Animal study confirms that genipin could suppress the invasion of
HCC cells. Our study sheds light on the potential inhibition of
genipin on hepatocellular carcinoma metastasis and some novel
mechanisms may be involved.
Results
Genipin Inhibits the HCC Cells Migration and Invasion in
Non-toxic Manner
In our study, we found that genipin exerts no significant
cytotoxicity to human hepatocellular carcinoma cells HepG2
and MHCC97L for either 24 hr or 48 hr treatment. Cells with
genipin exposure present no potent reduction in viability at the
dose of not more than 60 mg/mL in HepG2 cells and at not
more than 120 mg/mL in MHCC97L cells (Fig. 1A). This
indicates that genipin has no inhibitory action on cell
proliferation or cell survival. Interestingly, we found that
genipin exerts remarkable inhibitory action on cell migration
on 1-D surface as well as cell invasion through extracellular
matrix materials at the dose far lower than its cytotoxicity.
7.5 mg/mL and 15 mg/mL treatment to HepG2 cells or 15 mg/
mL and 30 mg/mL treatment to MHCC97L cells could
significantly reduce cancer cell migration and invasion, as
indicated by wound healing assay (Fig. 1B) and Matrigel Matrix
invasion assay (Fig. 1C). Our result indicates that genipin is a
potent inhibitor for hepatocellular carcinoma cell migration and
invasion in cytotoxic-independent manner.
Genipin Down-regulates MMP-2 Activity
The MMPs activities were detected with Gelatin Zymography
assay and inhibition of genipin on MMP-2/9 activity was observed
in HepG2 and MHCC97L cells with treatment of genipin
(Fig. 2A). The expression and activity of MMP-9 were rather
low in HCC cells and although suppression of MMP-9 activity
could be found in genipin-treated cells, there’s no statically
significant between treated cells and non-treated cells. In contrast,
the basal levels of MMP-2 expression and activity in HCC cell
were much greater than MMP-9, and genipin exhibit statistically
significant inhibition on MMP-2 activity. These observations
indicate that the anti-migration action of genipin may major
attribute to MMP-2 activity suppression. Genipin shows no
inhibitory effect on the activities of human recombinant MMP-
2/9. The enzymatic reactions of MMP-2/9 could not be directly
blocked or postponed by genipin treatment even at rather high
dose (Fig. 2B). To determine whether the reduced activity of
MMP-2 is attributable to the suppression of protein expression in
hepatocellular carcinoma cells, we detected the mRNA transcripts
and protein levels of MMP-2/9 in HepG2 and MHCC97L cells
with semi-quantitative PCR and western blot, respectively.
Genipin has no significant effect on the expression of MMP-2/9
at either mRNA transcripts or protein level (Fig. 2C). In addition,
genipin exhibits no remarkable effect on other migration and
invasion related conventional signaling in both HepG2 and
MHCC97L cells (Fig. 2D). This may indicate that genipin could
downregulate the MMP-2 activity by inhibiting its cleavage
activation but not suppressing its expression in hepatocellular
carcinoma cells.
Increased Expression of TIMP-1 by Genipin Contributes
to its Inhibitory Effect on MMP-2 Activity in HCC Cells
We next determined the expression of endogenous inhibitors of
MMP-2 activity, the TIMPs family and RECK, which have been
reported to suppress MMP-2 activity in pathological conditions
[14–18]. We found that the mRNA transcription of TIMP-1 was
induced genipin intervention, while expression of other TIMPs
and RECK remains unchanged (Fig. 3A). To further determine
this, we measured the endogenous TIMP-1 level by western blot
and secreted TIMP-1 in conditioned medium by ELISA assay.
Increased expression of TIMP-1 could be observed in cells with
genipin treatment, which is negative correlation with the down-
regualtion of MMP-2 activities (Fig. 3B&C). TIMP-1 was reported
to inhibit both MMP-2/9 activities in line [19], therefore the
inhibition of MMP-2 activities in human hepatocellular carcinoma
cells exposed to genipin may be attributable to up-regulation of
TIMP-1. This was confirmed by the observation that the MMP-2
activities was restored when the increases of TIMP-1 expression by
genipin was blocked by RNA interference in HCC cells (Fig. 4A).
Furthermore, it was found that the inhibition of genipin on HCC
cell motility and invasiveness could be attenuated by suppression
of TIMP-1 up-regulation (Fig. 4B&C). Our findings confirm that
increased expression of TIMP-1 is responsible for the inhibitory
effect of genipin on MMP- activities in HCC cells.
p38 MAPK Activation is Responsible for the in vitro
Inhibitory Action of Genipin on HCC Cells Migration and
Invasion
Dose- and time-dependent manner of activation of p38
MAPK pathways by genipin treatment was observed in human
hepatocellular carcinoma cells HepG2 and MHCC97L (Fig. 5A).
12H to 24H exposure of genipin was sufficient to activate p38
MAPK in HCC cells without altering the Erk1/2, AMPK, or
Akt pathway activity. To further confirm the role of p38 MAPK
activation in the anti-metastasis effect of genipin, we examined
the function of p38 MAP in activating TIMP-1 expression. The
presence of SB202190, the p38 MAP inhibitor could down-
regulate the mRNA transcripts of TIMP-1 (Fig. 5B) as well as
the TIMP-1 protein expression (Fig. 5C). Furthermore,
Increased expression of TIMP-1 in HCC cells treated with
genipin was suppressed in the presence of SB202190 (Fig. 5D).
To further decipher the role of p38 MAPK pathway in the
genipin’s inhibitory effect on cancer cell migration and invasion,
we used SB202910, the p38 MAPK inhibitor, to block the
activation of the p38 MAPK by genipin. We found p38 MAPK
inhibition by SB202190 could significantly attenuate the
inhibitory action of genipin on in vitro migration and invasion
of HepG2 and MHCC97L cells (Fig. 6A&6B).As well, the
suppression of MMP-2/9 activities by genipin in HCC cells was
attenuated by co-treatment with p38 MAPK inhibitor
SB202190 (Fig. 6C). These results indicate that activation of
p38 MAPK pathway by genipin may suppress migration and
invasion of HCC cells via increasing the expression of TIMP-1.
Our result indicates that p38 MAPK activation is responsible
for the in vitro inhibitory action of genipin on the migration
and invasion of human hepatocellular carcinoma cells HepG2
and MHCC97L.
Anti-Metastatic Effect of Genipin in HCC
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Figure 1. Genipin suppresses hepatocellular carcinoma cell migration and invasion at non-toxic doses. A shows that genipin exhibits
no potent cytotoxicity to human heaptocellular carcinoma cells HepG2 and MHCC97L. Cells were seeded in 96-well culture plate and treated with
genipin for 24 h or 48 h. Cell viability was determined by MTT assay. B shows that genipin remarkably reduce HepG2 and MHCC97L cell motility in
dose-dependent manner. Cells were seeded in 12-well culture plate with 100% confluence. Wound healing assay was introduced to determine the
Anti-Metastatic Effect of Genipin in HCC
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Genipin Suppresses the Invasiveness of Tumor Cells in
Orthotopicallly Implanted HCC Model
The anti-metastatic potential of genipin in HCC was further
examined with the orthotopically HCC-implanted mice. Mice
were treated with either vehicle or genipin (30 mg/kg/2 days, i.p.)
for 3 weeks. To examine the possible toxicity of genipin on the
animal, we determined the body weight once per 2 days. No
significant reduction of body weight was observed in genipin-
treated mice, indicating that genipin may not present potent toxic
action to the animal (Fig. 7A). Liver was dissected out at the end of
the experiment, and the results showed that genipin could suppress
the tumor size in HCC-implanted mice (Fig. 7B). Intrahepatic
invasion of HCC cells to the normal tissue was examined by H&E
staining. It was observed that in control group, tumor cells exhibit
active metastasis effect, and venous infiltrate invasion could be
found in mice treated with vehicle. Tumor cells are able to invade
to blood vessel (the arrow indicated) in control group, while in
genipin-treated mice, no potent invasion of tumor cell to the blood
vessel could be observed. Absence of intrahepatic metastasis of
tumor cell to the normal tissue could be found in genipin-treated
mice (Fig. 7C).
Discussion
Previous studies have reported some anti-migration and anti-
invasioneffect of genipin. Studies showed that genipin could suppress
the alpha-TN4 lens epithelial cells and subconjunctival fibroblast
migration induced byTGF-b [20,21]. Genipinwas shown to inhibit
breast cancer cell MDA-MB-231 migration and to change the
invasive phenotype of breast cancer cells [22] andUCP2may be the
possible target involved [23]. In this study,wereported for the first the
anti-migration and anti-invasion effect of genipin in hepatocellular
carcinoma. Genipin exhibits no significant toxicity to HCC cells
HepG2 andMHCC97L, however, potent inhibition on cell motility
andinvasiveness throughextracellularmatrixcouldbefoundinHCC
cells treated with genipin. Moreover, genipin was shown to suppress
intrahepatic invasion ofHCCcells in orthotopically implantedHCC
animal model. Mechanism study exhibits that genipin is capable of
down-regulating the gelatinase MMP-2 activities without suppress-
cell motility in the presence of genipin. The distance between the gap was quantified and the results were shown. *p,0.05, **p,0.01 when
compared with control; C shows that genipin could inhibit cell invasion through extracellular matrix. Cells were seeded in the chamber of transwells
coated with Matrigel matrix. The invasiveness of cells was determined by counted cells passing through Matrigel matrix to the basal side of
transwells. *p,0.05, **p,0.01 when compare with vehicle group.
doi:10.1371/journal.pone.0046318.g001
Figure 2. Genipin suppresses MMP-2 activities without inhibiting their expression in hepatocellular carcinoma cells. A shows that
genipin could inhibit MMP-2 activities in dose- and time-dependent manner in HepG2 and MHCC97L cells. Cells were treated with genipin for 24 or
48H then medium was collected. The MMP-2 and MMP-9 activities were examined by gelatin zymography. Intensity of the band was quantified.
*p,0.05; **p,0.01 when compared with control; B shows that genipin has no effect on in vitro recombinant MMP-2 and MMP-9 enzyme activity. The
MMP-2 and MMP-9 enzymatic dynamics in the presence of 160 mM of genipin were determined as described. No significant change on the dynamic
slope could be observed upon genipin treagtment. C shows that genipin does not inhibit the mRNA transcript and protein expression. Cells were
treated with genipin for either 24 H and then total RNA and protein were collected as described. The mRNA transcript expression was examined by
quantitative real-time PCR while protein expression was determined by immunoblotting. D shows that no significant alternation on the other major
signaling transductions of cell migration and invasion in genipin-treated HCC cells. HepG2 and MHCC97L cells were treated with genipin for 24 or
48H and protein was collected for immunoblotting analysis.
doi:10.1371/journal.pone.0046318.g002
Anti-Metastatic Effect of Genipin in HCC
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ing their expression; up-regulation of TIMP-1, the endogenous
inhibitor ofMMP-2,maybe responsible for the inhibition ofMMP-2
activity. Although TIMP-1 should be responsible for the MMP-9
activity, the up-regulation of TIMP-1 could not exhibit statistically
significance of MMP-9 inhibition in HCC cells with treatment of
genipin. Thismay be due to the relative low-expression of basal level
ofMMP-9.Activationof p38MAPKsignalingwas observed inHCC
cells exposed to genipin, and inhibition of p38 MAPK signaling by
SB202190 abolishes up-regulation of TIMP-1 by genipin, as well as
attenuates MMP-2 inhibition by genipin. Systematic scheme of
regulatorynetworkof genipin inHCCwas shown inFig.8.Our result
indicates the possible potential of genipin as an adjuvant therapy in
hepatocellular carcinoma.
TheMMPs family is a groupof enzymes involving in the tumor cell
migration, invasion and metastasis by degeneration of extracellular
matrix proteins such as collagens and proteoglycans [24]. Amongst
the MMPs, gelatinases MMP-2/9 show dominant role in cancer
progression[25], indicating thepotentialofMMP-2/9as therapeutic
target in the prevention of cancer metastasis. In our study, we found
for the first time genipin is a specific inhibitor toMMP-2 activities in
human hepatocellular carcinoma cells. Genipin has no effect on the
expression level of MMP-2, indicating that genipin may possibly
inhibit MMP-2 by directly being their inhibitor or by up-regulating
their endogenous inhibitors. Direct exposure of human MMP-2
recombinant proteins to genipin has no effect on their activities,
showing that genipin may be not act as a small molecule that can
inactivate MMP-2. Instead, we found that the inhibitory effect of
genipin on MMP-2 acts through up-regulating their endogenous
inhibitor TIMP-1. Up-regulation of TIMP-1 was shown to suppress
the tumor invasion and metastasis in various human cancers, which
may be correlated with its inhibition on MMP-2/9 [26–28].
Although we could observe dose-dependent suppression of MMP-9
activity, there’s no significancebetweennon-treated and treated cells
statistically. Furthermore, since the basal levels of MMP-2 were
dominantlyandsignificant suppressionofgenipinonMMP-2activity
couldbe foundinHCCcells,weconcludedthatgenipinmaytargeton
MMP-2 majorly, which contributes to the anti-metastatic effect of
genipin in hepatocellular carcinoma. Our results revealed that
silencing the expression of TIMP-1 by RNA interference could
significantly recover theactivities ofMMP-2 ingenipin-treatedHCC
cells, as well as the motility and invasiveness of HCC cells. This
exhibits that up-regulation of TIMP-1 is responsible for the anti-
metastatic potential of genipin in hepatocellular carcinoma.
The p38 MAPK signaling is a stress-activated signaling pathway
which responses when cells are receiving stress or cytokines. The
recent studies revealed the role of p38 MAPK as a suppressor in
tumor progression, which indicates its broader function other than
stress response [29]. It was shown that knockout of p38agenerates
tumors in nude mice, presenting the unsuspended role of p38
MAPK in tumorigenesis [30]. The kinase activity of p38 was also
demonstrated by an observation of slower tumor proliferation and
metastasis in cancer cells with sustained activated p38 MAPK
[31]. Furthermore, less active p38 MAPK was found in human
hepatocellular carcinoma tissue in compared with normal liver,
and the less active p38 was observed in tumor with larger size.
These observations indicate both expression and activity of p38
MAPK are suppressed in human cancer, where the inhibition of
p38 MAPK activity may be dominant in controlling tumor
progression [32]. In our study, we found that genipin could
potently activate p38 MAPK signaling at non-toxic dosages, which
may be responsible for the anti-invasion and anti-metastasis effect
of genipin in human HCC. The total level of p38 MAPK could
not be over-expressed by genipin, which indicates that genipin
may regulate the metastatic potential of HCC cell majorly through
activating its p38 activity. Inhibition of p38 activity by SB202190
significantly recovered the invasiveness and metastatic potential of
Figure 3. Genipin treatment up-regulates the expression of TIMP-1 in HCC cells. A shows the quantitative real-time PCR screening of
endogenous MMP-2/9 inhibitors. Cells were treated with genipin for 24H and total RNA was collected for anlaysis. The result shows that genipin
particularly up-regulate TIMP-1 mRNA transcription but has no effect on TIMP-2, -3, -4 and RECK mRNA transcript in HepG2 and MHCC97L cells. B
shows that genipin exposure is responsible for the increased secretion of TIMP-1 in HepG2 and MHCC97L cells. The cells were transfected with scr
negative control siRNA or siRNA against TIMP-1. Then cells were treated with genipin for 24H then medium was collected for ELISA determination of
TIMP-1. *p,0.05,p,0.01 when compared with control; C shows that genipin up-regulates expression of TIMP-1. The cells were transfected with scr
negative control siRNA or siRNA against TIMP-1. Then cells were treated with genipin for 24H and cell lysates were analyzed with immunoblotting.
doi:10.1371/journal.pone.0046318.g003
Anti-Metastatic Effect of Genipin in HCC
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HCC cells exposed to genipin, indicating the central role of p38
activation in genipin’s anti-metastatic effect. Activators of p38
MAPK signaling were previously reported for their anti-metastatic
potentials in human cancers. Quercetin was reported to inhibit the
uPA signaling, which was related to increased p38 activity by
quercetin in prostate cancer [33]. Celastrol activated-p38 MAPK
was responsible for its inhibition on beta1 integrin function, cell-
ECM adhesion, and phosphorylation of FAK [34]. Some previous
studies also found TIMP-1 up-regulation by activated p38 MAPK
in human cancer cells treated with chemotherapeutic agents
cannabidiol and cisplatin [35,36], which exhibit potent inhibition
on human cancer cell invasion in vitro. Our results demonstrate
that genipin presents similar anti-metastatic effect by activating
p38 MAPK to induce TIMP-1 expression in hepatocellular
carcinoma, indicating that genipin may be on the list of potential
therapeutic agents against human cancer.
Materials and Methods
Chemicals, Antibodies and Reagent
Genipin, gelatin and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) were purchased from Sigma-
Aldrich (USA). Rabbit monoclonal antibodies against MMP-2,
MMP-9, E-cadherin, integrin b4, N-cadherin and TIMP-1 were
purchased from Cell Signaling Techonolgies (USA). Rabbit
polyclonal antibody against uPA was purchased from Santa
Cruz (USA).
Cell Line and Cell Culture
Human hepatocellular carcinoma cell line HepG2 was
purchased from ATCC (USA); Human hepatocellular carcinoma
cell line MHCC97L was kindly gifted by Dr. Man Kwan
Department of Surgery, The University of Hong Kong, and has
been used in our previous published works [4,37]. Cells were
maintained in DMEM medium with 10% Fetal Bovine Serum
(Life Technologies, USA) and 1% penicillin/streptomycin (Life
Technologies, USA) and incubated in a humidified atmosphere
containing 5% CO2 at 37%.
Cell Viability Assay
The cell viability after Genipin treatment was determined by
MTT assay. Briefly, cells were seeded in 96-well plate and treated
with series concentration of Genipin (0, 3.75, 7.5, 15, 30, 60 and
120 mg/mL) and incubated 24 and 48 h. All experiments were
performed parallel with controls (0.1% DMSO). After incubation,
10 ml of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT, 5 mg/ml, Sigma, USA) were added to each well and
incubated at 37uC for 4 h. Then medium was removed and 100 ml
of DMSO was added to each well. The absorbance of formazan
formed was measured at 595 nm by Multiskan MS microplate
reader (Labsystems, Finland).
Figure 4. Upregulation of TIMP-1 expression is responsible for the MMP-2 inhibition by genipin in HCC cells. A shows that inhibition
of TIMP-1 expression by RNA interference abolishes inhibition of MMP-2 activity by genipin. Cells were transfected with either scr siRNA or siRNA
against TIMP-1 followed by genipin treated for 24H. The suppression of TIMP-1 by siRNA was verified as Fig. 3C shows. Medium was then collected for
gelatin zymography analysis. Intensity of the band was quantified. *p,0.05, **p,0.01 when compared with control; B shows that inhibition of TIMP-
1 attenuates genipin-suppressed HCC cell motility. Distance between the gap was quantified. *p,0.05, **p,0.01 when compared with control; C
shows that inhibition of TIMP-1 expression attenuates HCC cell invasiveness suppressed by genipin. The invaded cell number was quantified.
*p,0.05, **p,0.01 when compared with control.
doi:10.1371/journal.pone.0046318.g004
Anti-Metastatic Effect of Genipin in HCC
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Wound Healing Assay
Cells were cultured in 24-well plate with 100% confluence. A
gap was scrapped using a micro-pipette tip on the cell monolayer.
Medium was removed and the monolayer was washed with warm
PBS for 3 times. Then growth medium containing vehicle or
different concentrations of genipin was added to each well and
graphics were obtained after 0, 24 and 48 h incubation.
Matrigel Matrix Invasion Assay
The invasion chamber assay was conducted with Millicell Cell
Culture Insert (24-well PCF 8.0 ml, Millipore). Briefly, the inserts
standing in 24-well cell culture plate were coated with 100 ml
1 mg/mL Matrigel Matrix (BD Falcon, USA) in serum-free
DMEM medium and air-dried. 100 ml serum-free medium
containing 56104 cells were added to the insert.0.5 ml of DMEM
medium containing 10% FBS and indicated concentrations of
genipin was added to each well of the 24-well plate. This follows
incubation in 5% CO2 at 37% for 48H. Then the non-invading
cells on the upper surface of Matrigel matrix were removed by
cotton swabs. The cells that invaded across the collagen to the
lower surface of the membrane were fixed by ice cool 100%
ethanol and stained by 2% Crystal Violet (Sigma Aldrich, USA).
Photographs of the stained invaded cells (5 random fields/culture)
were taken under an inverted microscope at 200x and the mean
number of cells of the 5 fields was recorded. The data were then
expressed as the average number (6SD) of cells from 5 fields that
invaded from each of 3 experiments performed.
Gelatin Zymography
The gelatin zymography was performed to determine the
activity of MMP-2 and MMP-9. Briefly, medium was collected
and mixed with 3X loading buffer. Protein in medium was then
separated in 10% SDS-page gel containing 1 mg/ml gelatin. After
running, the gel was incubated in the 2.5% triton-X in deionized
water for renaturing with gentle agitation for 30 minutes at room
temperature. Then the gel was incubated in developing buffer
(50 mM Tris-HCl, 0.2 M NaCl, 5 mM CaCl2, 0.02% Brij35)
overnight with gentle shaking. The gel was stained Coomassie Blue
R-250 for 30 minutes and then washed. The gel was visualized
under a chemiluminescence imaging system (Biorad, USA) and
Figures were captured.
In vitro MMP-2/9 Activity Assay
The MMP-2/9 activity dynamics were evaluated using MMP-
2/MMP-9 colormetric drug discovery kits (Enzo, USA) under the
manufacturer’s instruction. In brief, the human recombinant
MMP-2 or MMP-9 was mixed with 30 mg/mL genipin or NNGH
100 nM inhibitor as negative control. The mixture was incubated
Figure 5. Activation of p38 MAPK signaling by genipin confers the overexpression of TIMP-1 in HCC cells. A shows that genipin
activates p38 MAPK signaling in dose- and time- dependent manner. Cells were treated with genipin for 12 for 24H then protein was collected. The
activation of p38 MAPK was analyzed by immunoblotting. B shows that inhibition of p38 MAPK repressed mRNA transcripts up-regulated by genipin
treatment. Cells were treated with genipin for 12H in the presence or absence with SB202190 (20 mM) then total RNA was collected. The TIMP-1
mRNA transcripts were analyzed by qRT-PCR. *p,0.05, **p,0.01 when compared with control; C shows that inhibition of p38 MAPK suppressed the
up-regulation of TIMP-1 protein expression induced by genipin. Cells were treated with genipin for 24H in the presence or absence with SB202190
(20 mM) then protein was collected for immunoblotting analysis. D shows that inhibition of p38 MAPK reduced TIMP-1 secretion. Cells were treated
with genipin for 12, 24 or 48H in the presence or absence with SB202190 (20 mM) then medium was collected and TIMP-1 secretion was analyzed by
ELISA assay. *p,0.05, **p,0.01 when compared with control.
doi:10.1371/journal.pone.0046318.g005
Anti-Metastatic Effect of Genipin in HCC
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Figure 6. Inhibition of p38 MAPK attenuates genipin-suppressed HCC cell migration and invasion. A shows that inhibition of p38 MAPK
signaling attenuates cell migration and invasion inhibition by genipin. Cells were pre-treated with p38 MAPK inhibitor, SB202190 (20 mM), for 30 min
followed by being exposed to genipin. The cell migration was determined by wound healing assay. The distance between the gap was quantified.
*p,0.05, **p,0.01 when compared with control. B shows that inhibition of p38 MAPK restores invasiveness of HCC cells. Cells were pre-treated with
p38 MAPK inhibitor, SB202190 (20 mM), for 30 min followed by being exposed to genipin. The cell invasion through ECM was determined by chamber
assay. Invaded cell number was counted. *p,0.05, **p,0.01 when compared with control. C shows that MMP-2 activity inhibition in HCC cells
exposed to genipin was attenuated in the presence of SB202190. Cells were pre-treated with SB202190 (20 mM) for 30 min followed by genipin
exposure for 24H. The MMP-2/9 activity in conditioned medium was determined by gelatin zymography.
doi:10.1371/journal.pone.0046318.g006
Figure 7. Genipin exhibits anti-invasive effect in orthotopically HCC-implanted mice. A shows Genipin has no toxic effect on the
orthotopically HCC implanted model. MHCC97L cells were subcutaneously injected into the right flank of the nude mice to allow xenografted tumor
growth. Once the solid tumor reaches about 1 cm in diameter, it was dissected out and cut into 1–2 mm small cubes, which was then implanted to
the left liver lobe of the nude mice to allow orthotopical growth of HCC. Seven days later, the nude mice was randomized into two groups (n = 5).
Treatment was conducted seven days after implantation (genipin 30 mg/kg/2 days, i.p.) and lasted for 3 weeks, while control group received same
volume of PBS. Body weight of the mice was examined once per two days. No significant loss in body weight during treatment could be observed,
indicating genipin may not exhibit potent toxicity to the mice. B shows that genipin treatment could reduce the tumor size in HCC-implanted mice.
C shows that genipin suppresses tumor cell invasion to the normal tissue in orthotopically HCC implanted model. The liver of mice was dissected out
and histological analysis was conducted with H & E staining. Significantly reduction of intrahepatic invasion of MHCC97L could be observed in
genipin-treated mice.
doi:10.1371/journal.pone.0046318.g007
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at 37uC for 45 min then substrate was added. The plate was
immediately read at 405 nm by Multiskan MS microplate reader
(Labsystems, Finland). Continuous recording was made at 1 min
interval for 10 min. The dynamic changes of MMP-2/9 were
determined by the slope of line fit to liner portion. The experiment
was performed in duplicate.
TIMP-1 ELISA Assay
The TIMP-1 expression was determined by human TIMP
ELISA kit (ExCell Biology, Shanghai, China) under the manu-
facturer’s instruction. Briefly, samples were added to the microwell
plate with human TIMP-1 monoclonal antibody coating in
combination with biotinylated antibody and incubates for 2 h at
room temperature. Equal volume of assay diluents buffer was
added to one well as empty control. All experiments were
conducted in triplicate to avoid handling error. Then wells were
washed six times and the HRP-conjugated streptavidin was added
to each well except the empty control for 1 h incubation at room
temperature. Then plate was washed as described above and TMB
substrate solution was added for 30 min incubation in dark at
room temperature. At the end of incubation, 100 ml stop solution
was added to each well and the absorbance at 450 nm was read
with reference at 630 nm using Multiskan MS microplate reader
(Labsystems, Finland).
Quantitative Real-time PCR
Total RNA of cells with or without berberine intervention was
extracted and purified using RNeasy Mini Kit (Qiagen, Germany)
following the manufacturer’s instruction. RNA samples were
subject to QuantiTech Reverse Transcription Kit (QIAGEN,
Germany) for the reverse transcription. The quantitative real-time
PCR (qRT-PCR) was conducted by LightCycler 480 SYBR Green
I master (Roche, USA) with 1 mM primers (Table 1) LightCycler
480 real-time PCR system (Roche, USA). The expression of b-
actin was used as endogenous control for the normalization of
gene expression.
Immunoblotting
Cells was harvested using a micro-scrapper (Corning, USA) and
then lysed with RIPA buffer supplemented with proteinase
inhibitor (1% PMSF, 0.5% apotinin and 0.5% leupitine) and
phosphatase inhibitor (1 mM Na3VO4 and 1 mM NaF) on ice for
30 minutes and then centrifuged at 14,000 rpm at 4uC for 25
minutes. The supernatant was transferred to a new tube and
protein concentration was determined using BSA as standard.
Equal amounts of protein were resolved by SDS-PAGE and
transferred onto a polyvinylidene fluoride membrane (PVDF,
Figure 8. Overall scheme of the regulatory network involved in the inhibitory effect of genipin on HCC invasion.
doi:10.1371/journal.pone.0046318.g008
Table 1. Primers used for real-time quantitative PCR.
gene symbol Sequence (59 to 39)
ACTIN FWD CCAACCGCGAGAAGATGA
REV CCAGAGGCGTACAGGGATAG
TIMP-1 FWD GGGCTTCACCAAGACCTACA
REV TGCAGGGGATGGATAAACA
TIMP-2 FWD GAAGAGCCTGAACCACAGGT
REV CGGGGAGGAGATGTAGCAC
TIMP-3 FWD TGCAACTCCGACATCGTG
REV AAGGGCCCCTCCTTTACC
TIMP-4 FWD CAGACCCTGCTGACACTGAA
REV CTCCAGAGGCACTCGTTAGG
RECK FWD CAAGTGTCCTTCGCTCTTGG
REV CACATAATGGGCAACAAGCA
MMP-2 FWD CCCCAAAACGGACAAAGAC
REV CTTCAGCACAAACAGGTTGC
MMP-9 FWD GAACCAATCTCACCGACAGG
REV GCCACCCGAGTGTAACCATA
doi:10.1371/journal.pone.0046318.t001
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Biorad). Then the membrane was blocked with 5% BSA overnight
at 4uC. The membrane was then incubated with primary
antibodies at 4uC overnight followed by incubation with appro-
priate secondary antibodies (Abcam, UK) at room temperature for
2 hours. The immunoreactivites were detected using ECL
Adanced kit (GE Healthcare, UK) and visualized using a
chemiluminenescence imaging system (Biorad, USA).
Evaluation of Anti-metastatic Potential of Genipin in vivo
The anti-metastatic potential of genipin was evaluated with
orthotopically HCC-implantation animal model, which has been
described in our previous study [37]. In brief, approximately
16107 MHCC97L in 0.2 mL was subcutaneously injected into the
right flank of the male nude mice to allow solid tumor growth.
Once the tumor researched about 1 cm in diameter, the mice was
sacrificed by injecting i.p. overdose of Phenobarbital (200 mg/kg)
and the tumor was removed and cut into 1–2 mm small cubes,
which were then implanted into the left liver lobe of the male nude
mice, which were anaesthetized by etamine/xylazine (67 mg/kg/
6 mg/kg, i.p.). To minimize analgesics after animal surgery, mice
were received meloxicam (1.5 mg/kg) orally for a week. Seven
days later, the nude mice was randomized into two groups (n = 5).
One group received genipin 30 mg/kg/2 days, i.p. for 3 weeks
and the other received same volume of PBS as control. At the end
of experiment, the mice were sacrificed by injecting overdose of
Phenobarbital (200 mg/kg) and the liver was dissected out. The
tumor size was calculated. The liver was then cut and subject to H
& E staining to evaluate the intrahepatic invasion of MHCC97L
cells (406 magnification in light microscope). All protocols in
animal handling complied with the guidelines of the Laboratory
Animal Centre of the University of Hong Kong. Animals were
processed (including drug treatment and sacrifice) in accordance
with the international guidelines for laboratory animals. The
animal experimental protocol was approved by the Committee on
the Use of Live Animal in Teaching and Research (CULATR) in
The University of Hong Kong.
Statistical Analysis
Results were analyzed using student T-test and expressed as
mean 6 SD.
Conclusions
In conclusion, we reported the anti-metastatic potential of
genipin in human hepatocellular carcinoma. Genipin exhibits no
potent cytotoxicity to hepatocellular carcinoma cell HepG2 and
MHCC97L and no-toxic doses of genipin could significantly
suppress HepG2 and MHCC97L cell migration as well as invasion
through extracellular matrix. Genipin is capable of inhibiting
MMP-2 activity without alteration their mRNA and protein
expression in HCC cells, which may play a key role in its anti-
metastatic effect. Up-regulation of TIMP-1, the endogenous
inhibitor of MMP-2 in HCC cells with treatment of genipin,
could be observed and abolishment of TIMP-1 expression by
RNA interfering attenuates anti-invasive action of genipin.
Activation of p38 MAPK signaling could be observed in
genipin-treated HCC cells, which is responsible for the overex-
pression of TIMP-1 and inhibition of cell migration and invasion.
Orthotopically HCC-implantation model demonstrates that geni-
pin could suppress intrahepatic invasion of HCC cells into the
normal tissue. Taken together, our results demonstrate the anti-
metastatic potential of genipin in hepatocellular carcinoma, and
the MMP-2 inactivation by p38-driven TIMP-1 overexpression
may be involved as the major mechanism in genipin’s anti-
metastatic effect.
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